Schedule 13G/A: GS Group and Goldman Sachs & Co. Hold 0 Shares of CMRX
Rhea-AI Filing Summary
The Goldman Sachs Group, Inc. and Goldman Sachs & Co. LLC filed a Schedule 13G/A reporting that they beneficially own 0.00 shares of Chimerix common stock, representing 0.0% of the class. The cover pages show 0.00 sole and shared voting power and 0.00 sole and shared dispositive power, indicating no reportable economic or voting stake in the issuer as disclosed.
The filing includes a joint filing agreement and an exhibit identifying Goldman Sachs & Co. LLC as a subsidiary of The Goldman Sachs Group, Inc. It also states ownership is five percent or less and that the securities are held in the ordinary course of business and were not acquired to influence control.
Positive
- None.
Negative
- None.
Insights
TL;DR: Report shows no beneficial holdings—no direct market exposure or voting influence from Goldman Sachs entities.
The Schedule 13G/A discloses 0.00 shares and 0.0% ownership, with 0.00 reported voting and dispositive powers. For investors, this filing confirms that these large financial entities do not hold a reportable position in Chimerix and, per the certification, are not acting to influence control. The joint filing and subsidiary identification are administrative disclosures clarifying corporate relationships among the filers.
TL;DR: Disclosure is routine and non-material; it documents corporate relationships and ordinary-course holdings.
The document provides standard compliance information: a joint filing agreement and an exhibit stating the parent-subsidiary relationship. The filers certify the holdings are ordinary-course and not intended to affect corporate control. Because reported holdings are 0.00 shares, there are no governance or control implications arising from this filing itself.